Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
41.19
+4.88 (13.44%)
Jan 22, 2026, 3:54 PM EST - Market open
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $207.64M in the quarter ending September 30, 2025, with 13.75% growth. This brings the company's revenue in the last twelve months to $741.17M, up 17.92% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$741.17M
Revenue Growth
+17.92%
P/S Ratio
5.09
Revenue / Employee
$1,482,344
Employees
500
Market Cap
4.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
| Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
| Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
| Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
| Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
| Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
| Dec 31, 2012 | 3.31M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
| Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
| Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
| Dec 31, 2006 | 294.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 909.05M |
| ADMA Biologics | 488.56M |
| Ligand Pharmaceuticals | 251.23M |
| Liquidia | 69.22M |
| Arcellx | 35.90M |
| NewAmsterdam Pharma Company | 35.24M |
| Centessa Pharmaceuticals | 15.00M |
| Xenon Pharmaceuticals | 7.50M |
CORT News
- 4 hours ago - Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps - Benzinga
- 7 hours ago - Corcept's cancer drug meets main goal in late-stage trial - Reuters
- 7 hours ago - Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 7 days ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch
- 7 days ago - CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PRNewsWire
- 7 days ago - Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT - Business Wire
- 8 days ago - Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman - PRNewsWire
- 9 days ago - CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - Newsfile Corp